Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chien-Hsing Chang

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
Cancer Research|June 19, 2008
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinomaDavid V Gold, David M Goldenberg, Habibe Karacay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)Robert M Sharkey, William J McBride, Thomas M Cardillo, et al.
International Journal of Cancer|July 29, 2011
Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivoDavid M Goldenberg, David Zagzag, Kerstin M Heselmeyer-Haddad, et al.
Blood|October 23, 2008
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibodyDavid M Goldenberg, Edmund A Rossi, Rhona Stein, et al.
Bioconjugate Chemistry|April 28, 2015
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other CancersThomas M Cardillo, Serengulam V Govindan, Robert M Sharkey, et al.
Molecular Cancer Therapeutics|December 14, 2002
Molecular advances in pretargeting radioimunotherapy with bispecific antibodiesChien-Hsing Chang, Robert M Sharkey, Edmund A Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodiesPierre-Yves Brard, Habibe Karacay, Rhona Stein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 16, 2009
A novel method of 18F radiolabeling for PETWilliam J McBride, Robert M Sharkey, Habibe Karacay, et al.
Nature Medicine|November 1, 2005
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibodyRobert M Sharkey, Thomas M Cardillo, Edmund A Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograftHabibe Karacay, Pierre-Yves Brard, Robert M Sharkey, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Cancer Research|June 19, 2008
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinomaDavid V Gold, David M Goldenberg, Habibe Karacay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)Robert M Sharkey, William J McBride, Thomas M Cardillo, et al.
International Journal of Cancer|July 29, 2011
Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivoDavid M Goldenberg, David Zagzag, Kerstin M Heselmeyer-Haddad, et al.
Blood|October 23, 2008
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibodyDavid M Goldenberg, Edmund A Rossi, Rhona Stein, et al.
Bioconjugate Chemistry|April 28, 2015
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other CancersThomas M Cardillo, Serengulam V Govindan, Robert M Sharkey, et al.
Molecular Cancer Therapeutics|December 14, 2002
Molecular advances in pretargeting radioimunotherapy with bispecific antibodiesChien-Hsing Chang, Robert M Sharkey, Edmund A Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodiesPierre-Yves Brard, Habibe Karacay, Rhona Stein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 16, 2009
A novel method of 18F radiolabeling for PETWilliam J McBride, Robert M Sharkey, Habibe Karacay, et al.
Nature Medicine|November 1, 2005
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibodyRobert M Sharkey, Thomas M Cardillo, Edmund A Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograftHabibe Karacay, Pierre-Yves Brard, Robert M Sharkey, et al.
Pageof 10